Table 1.
Demographic, clinical and pathological information of TCGA cohort.
| TCGA Cohort | ||
|---|---|---|
| No. of patients | 408 | |
| Age | year | |
| Mean | 75.0 | |
| Range | 40~98 | |
| Gender | n(%) | |
| Male | 301(73.8) | |
| Female | 107(26.2) | |
| Stage | n(%) | |
| I | 2(0.5) | |
| II | 130(31.9) | |
| III | 140(34.3) | |
| Ⅳ | 134(32.8) | |
| Unknown | 2(0.5) | |
| TMIT types | n(%) | |
| I | 150(36.8) | |
| II | 150(36.8) | |
| III | 54(13.2) | |
| Ⅳ | 54(13.2) | |
| FGFR3 | n(%) | |
| Mutation | 60(14.7) | |
| Wild type | 348(85.3) | |
| RB1 | n(%) | |
| Mutation | 71(17.4) | |
| Wild type | 337 (82.6) | |
| Mutation burden | x±σ | 356.9±384.7 |
| mRNA expression | x±σ | |
| CD8A | 3.1±5.8 | |
| PD-L1 | 3.1±5.1 | |
| IFN-γ | 0.6±1.5 | |
| Cytolytic activity | x±σ | 6.6±11.8 |
| Neoantigen number | x±σ | 45.8±42.8 |
The cytolytic activity of each sample was calculated using the value of the geometric mean of granzyme and perforin1. The predicted neoantigen number was referenced in a previous report by Chan-Young Ock. TCGA, the Cancer Genome Atlas; TMIT, tumor microenvironment immune type; x±σ, mean ± standard deviation.